Update your location to show providers, locations, and services closest to you.
Cancer Specialist (Oncologist), Hematology and Oncology Specialist
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab…
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense…
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell…
12 publications
2021
JCO oncology practice
PubMed • Publisher's site2021
Cancers
PubMed • Publisher's site2019
Future science OA
PubMed • Publisher's site2017
Head and neck pathology
PubMed • Publisher's site2014
Annals of the American Thoracic Society
PubMed • Publisher's site